Viking (VKTX) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
In the last reported quarter, the company's earnings met expectations. Factors to Consider Without an approved/marketed product in its portfolio, the focus is expected to be on updates related to Viking's pipeline consisting of three candidates — VK2735 (for obesity), VK2809 (for non-alcoholic steatohepatitis [NASH]) and VK0214 (for X-linked adrenoleukodystrophy (X-ALD)]. Viking Therapeutics is evaluating both oral and subcutaneous formulations of VK2735 in treating obesity. Last month, management reported data from a phase I study evaluating the oral formulation of the drug, which demonstrated dose-dependent reductions in mean body weight after 28 days of daily dosing. Patients who received the drug at the highest dose level (i.e., 40mg) lost up to 5.3% of their body weight compared with 2.1% in the placebo group. In fact, 57% of patients who received the 40mg dose lost at least 5% of their body weight. The drug was well-tolerated across all doses, with no serious adverse event
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Eli Lilly loses $120B in value over Viking's GLP-1 progress [Yahoo! Finance Canada]Yahoo! Finance Canada
- Watch These Eli Lilly Stock Price Levels as Weight-Loss Drug Competition Rises [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its price target raised by analysts at Raymond James from $116.00 to $118.00. They now have a "strong-buy" rating on the stock.MarketBeat
- Hasbro, UMG, Keurig DrPepper: Earnings in review Viking Therapeutics weight-loss drug moves to Phase 3 trial US GDP growth proves economy 'still robust' in Q2: Economist Chip stock sell-off opens door for long-term plays: Analyst Unilever & Nestle resulAcquire Media Monitor
- Inside JD Vance's Short-Lived Career as a Venture Capitalist [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 7/24/24 - Beat
VKTX
Sec Filings
- 7/24/24 - Form 10-Q
- 7/24/24 - Form 8-K
- 6/4/24 - Form 8-K
- VKTX's page on the SEC website